Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT: Spironolactone for Arrhythmias in ICD Patients
NCT04495712Phase 4Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jul 2004
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ventricular tachycardia (VT) and ventricular fibrillation (VF) comparing Spironolactone with Placebo (2 arms). Primary endpoint: Time to First Appropriate Implantable Cardioverter Defibrillator (ICD) Therapy at 35 months. Started Jul 2004; status: completed.
02
Drugs
spironolactone
03
Conditions
ventricular tachycardia (VT)ventricular fibrillation (VF)
Beyond the preview
Go deeper on NCT04495712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495712.